Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Pre-B-cell leukemia transcription factor 1 (PBX1) is a nuclear protein member of the TALE (three amino acid loop extension) class of homeodomain-containing transcription factors. PBX1 forms heterodimers with HOX proteins and other transcription factors (e.g., MEIS, PREP) to regulate gene expression, particularly during embryonic development and organogenesis. In adults, PBX1 is implicated in tissue homeostasis, hematopoiesis, and immune function. PBX1 has a well-established role in oncogenesis; aberrant PBX1 activity, often in complex with HOX partners, contributes to acute lymphoblastic leukemia and a range of solid tumors. While not a classical drug target, PBX1 is currently being explored as a molecular target for inhibitors in cancer and possibly autoimmune disease due to its roles in cell fate determination and proliferation.
Future therapeutic strategies involve disruption of the PBX1/HOX protein–protein interaction to block oncogenic transcriptional activity in cancer cells.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Pre-B-cell leukemia transcription factor 1 (PBX1).